Journal of Medicinal Chemistry
Article
carbonate (4−20 mmol, 2 equiv). After being stirred for 1 h at 5−
10 °C, the mixture was allowed to warm to room temperature and
then stirred overnight.
The mixture was stirred at room temperautre for 7.5 h and evaporated
to dryness. The crude product was purified by silica gel
chromatography (EtOAc/MeOH (9/1) + 2% TEA) to give pure 14
(143 mg, 78%). Mp: 124−126 °C. 1H NMR (300 MHz, DMSO-d6): δ
2.41−2.57 (m, 10H, N−CH2), 3.35−3.53 (m, 14H, CH2), 7.00−7.06
(m, 4H, HAryl), 7.14−7.20 (m, 1H, HAryl), 7.24−7.32 (m, 2H, HAryl),
7.37−7.44 (m, 4H, HAryl), 7.88−7.96 (m, 2H, HAryl), 8.55 (t, 1H, 3J =
5.5 Hz, NH), 11.62 (br s, 2H, NH) ppm. 13C NMR (75.5 MHz,
DMSO-d6): δ 43.37, 47.29, 53.72, 57.11, 68.11, 68.88, 69.64, 69.74,
5-(4-Phenoxyphenyl)-5-prop-2-ynylaminopyrimidine-2,4,6-
trione (8). For the preparation of 8, 5-(4-phenoxyphenyl)pyrimidine-
2,4,6-trione (2.96 g, 10.0 mmol) and propargylamine (640 μL, 551 mg,
10.0 mmol) were subjected to the general procedure. For workup, the
reaction mixture was poured onto ice−water and adjusted to pH 4,
using dilute hydrochloric acid (6 N). The resulting precipitate was
filtered off, stirred in diethyl ether, and dried in vacuo, giving 8 as an
off-white solid (1.73 g, 50%). Mp: 248−249 °C (dec). 1H NMR (300
MHz, DMSO-d6): δ 3.17 (t, 1H, 4J = 1.7 Hz, CCH), 3.34 (br s, 1H,
NH), 3.38−3.46 (m, 2H, NH−CH2), 6.99−7.05 (m, 4H, HAryl), 7.14−
7.20 (m, 1H, HAryl), 7.37−7.46 (m, 4H, HAryl), 11.65 (br s, 2H, NH)
ppm. 13C NMR (75.5 MHz, DMSO-d6): δ 33.54, 68.78, 75.40, 81.64,
118.31, 119.15, 124.00, 128.11, 130.18, 132.42, 149.73, 155.93, 157.29,
170.64 ppm. HRMS-ESI: calcd for C19H15N3O4Na ([M + Na]+),
372.0955; found 372.0955. The purity of 8 was determined by
analytical HPLC to be 96%, tR = 7.90 0.02 min (n = 3).
2
73.95, 115.17 (d, J = 21.6 Hz), 118.07, 119.29, 124.07, 129.65, 129.69,
129.82 (d, 3J = 9.0 Hz), 130.19, 130.87 (d, 4J = 2.8 Hz), 149.44, 155.81,
1
157.39, 163.82 (d, J = 248 Hz), 165.18, 169.98 ppm. 19F NMR (282
MHz, DMSO-d6): δ −109.64 ppm. HRMS-ESI: calcd for C35H40FN5O8
([M + H]+), 678.2934; found 678.2935. Anal. Calcd for C35H40FN5O8: C
62.03, H 5.95, N 10.33. Found: C 61.63, H 5.85, N 10.31
General Procedure for the Preparation of Triazoles 28−36. To
a solution of the acetylene compound (0.5−1.0 mmol, 1 equiv) in
DMF (8 mL·mmol−1) were added aqueous CuSO4·5H2O (30−50 mol %),
aqueous sodium ascorbate (40−60 mol %), and the corresponding
azide (0.5−1.2 mmol, 1.0−1.2 equiv) in sequence. After the mixture
was stirred at room temperature, the solvents were removed and the
residue was purified by silica gel chromatography (EtOAc + 2% TEA →
5-(4-Phenoxyphenyl)-5-{4-[2-(2-{2-[2-(2-{2-[2-(2-prop-2-ynyloxy-
ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethyl]piper-
azin-1-yl}pyrimidine-2,4,6-trione (10). For the preparation of 10,
5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione (593 mg, 2 mmol) and 5
(1.18 g, 2 mmol) were subjected to the general procedure. For
workup, the reaction mixture was diluted with EtOAc, followed by
addition of aqueous citric acid (0.1 mmol mL−1). After separation of
the organic phase, the aqueous phase was extracted with EtOAc (2×).
The combined organic extracts were washed with water, dried
(MgSO4), filtered, and concentrated. The residue was purified by
silica gel chromatography (EtOAc/MeOH, 4/1) to afford 10 as a waxy
oil (1.23 g, 80%). 1H NMR (400 MHz, CDCl3): δ 2.43 (t, 1H, 4J = 2.4
Hz, CCH), 2.74−2.81 (m, 10H, N−CH2), 3.56−3.69 (m, 30H,
1
EtOAc/MeOH (4/1) + 2% TEA). H, 13C, and 19F NMR data of
triazoles 28−36 are listed in the Supporting Information.
5-{[1-(2-{2-[2-(2-Fluoroethoxy)ethoxy]ethoxy}ethyl)-1H-
1,2,3-triazol-4-ylmethyl]amino}-5-(4-phenoxyphenyl)-
pyrimidine-2,4,6-trione (28). For the preparation of 28, 8 (349 mg,
1 mmol), CuSO4·5H2O (75 mg, 0.3 mmol, 30 mol %, in 1 mL of H2O),
sodium ascorbate (79 mg, 0.4 mmol, 40 mol %, in 1 mL of H2O), and 21
(221 mg, 1 mmol) were subjected to the general procedure. After the
mixture was stirred for 2.5 h, the reaction yielded 28 as an off-white foam
(413 mg, 72%). Mp: 117 °C. HRMS-ESI: calcd for C27H31FN6O7 ([M +
Na]+), 593.2130; found 593.2138. Anal. Calcd for C27H31FN6O7: C
56.84, H 5.48, N 14.73. Found: C 56.47, H 5.43, N 14.53.
4
CH2), 4.18 (d, 2H, J = 2.4 Hz, CH2−CCH), 6.94−6.96 (m, 2H,
HAryl), 7.00−7.02 (m, 2H, HAryl), 7.11−7.16 (m, 1H, HAryl), 7.32−7.36
(m, 2H, HAryl), 7.46−7.48 (m, 2H, HAryl). 13C NMR (101 MHz,
CDCl3): δ 46.95, 53.64, 57.40, 58.49, 67.54, 69.18, 70.41, 70.43, 70.47,
70.50, 70.51, 70.53, 70.56, 70.58, 70.59, 70.60, 70.64, 74.31, 74.76,
79.78, 118.36, 119.66, 124.05, 128.83, 130.01, 130.12, 149.40, 156.40,
158.38, 169.70 ppm. HRMS-ESI: calcd for C39H54N4O12 ([M + H]+),
771.3811; found 771.3809. The purity of 10 was determined by
analytical HPLC to be 98%, tR = 8.12 0.01 min (n = 3).
5-({1-[2-(2-{2-[2-(2-Fluoropyridin-3-yloxy)ethoxy]ethoxy}-
ethoxy)ethyl]-1H-1,2,3-triazol-4-ylmethyl}amino)-5-(4-
phenoxyphenyl)pyrimidine-2,4,6-trione (29). For the prepara-
tion of 29, 8 (349 mg, 1 mmol), CuSO4·5H2O (100 mg, 0.4 mmol,
40 mol %, in 1 mL of H2O), and sodium ascorbate (99 mg, 0.5 mmol,
50 mol %, in 1 mL of H2O) and 23 (314 mg, 1 mmol) were subjected
to the general procedure. After the mixture was stirred for 23 h, the
reaction yielded 29 as a light yellow solid (438 mg, 66%). Mp: 104 °C.
HRMS-ESI: calcd for C32H34FN7O8Na ([M + Na]+), 686.2345; found
686.2346. The purity of 29 was determined by analytical HPLC to be
96%, tR = 8.30 0.03 min (n = 3).
5-(4-{2-[2-(2-{2-[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-
ylmethoxy]ethoxy}ethoxy)ethoxy]ethyl}piperazin-1-yl)-5-(4-
phenoxyphenyl)pyrimidine-2,4,6-trione (30). For the prepara-
tion of 30, 9 (595 mg, 1 mmol), CuSO4·5H2O (75 mg, 0.3 mmol,
30 mol %, in 1 mL of H2O), sodium ascorbate (79 mg, 0.4 mmol,
40 mol %, in 1 mL of H2O), and a solution of 24 (107 mg, 1.2 mmol)
were subjected to the general procedure. After stirring for 72 h, the
reaction yielded 30 as a white solid (440 mg, 64%). Mp: 118 °C.
HRMS-ESI: calcd for C33H42FN7O8 ([M + H]+), 684.3152; found
684.3168. Anal. Calcd for C33H42FN7O8: C 57.97, H 6.19, N 14.34.
Found: C 57.55, H 6.18, N 14.04.
5-[4-(2-{2-[2-(2-{2-[2-(2-{2-[1-(2-Fluoroethyl)-1H-1,2,3-tria-
zol-4-ylmethoxy]ethoxy}ethoxy)-ethoxy]ethoxy}ethoxy)-
ethoxy]ethoxy}ethyl)piperazin-1-yl]-5-(4-phenoxyphenyl)-
pyrimidine-2,4,6-trione (31). For the preparation of 31, 10 (385 mg,
0.5 mmol), CuSO4·5H2O (37 mg, 0.15 mmol, 30 mol %, in 0.5 mL of
H2O), sodium ascorbate (40 mg, 0.2 mmol, 40 mol %, in 0.5 mL of H2O)
and a solution of 24 (53 mg, 0.6 mmol) were subjected to the general
procedure. After the mixture was stirred for 24 h, the reaction yielded 31
as a colorless oil (152 mg, 35%). HRMS-ESI: calcd for C41H59FN7O12
([M + H]+), 860.4200; found 860.4182. The purity of 31 was determined
by analytical HPLC to be 95%, tR = 7.62 0.01 min (n = 3).
5-[4-(6-Fluoropyridin-2-yl)piperazin-1-yl]-5-(4-
phenoxyphenyl)pyrimidine-2,4,6-trione (13). For the prepara-
tion of 13, 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione (741 mg,
2.50 mmol) and 7 (736 mg, 2.50 mmol) were subjected to the general
procedure. For workup, the reaction mixture was diluted with EtOAc,
followed by an addition of aqueous citric acid (0.1 mmol mL−1). After
separation of the organic phase, the aqueous phase was extracted with
EtOAc (2×). The combined organic extracts were washed with water,
dried (MgSO4), filtered, and concentrated. The residue was purified by
silica gel chromatography (CH/EtOAc, 2/1) and the concentrated
eluent was subsequently stirred in diethyl ether to afford 13 as a white
solid (812 mg, 68%). Mp: 235 °C. 1H NMR (600 MHz, DMSO-d6): δ
2.67−2.69 (m, 4H, N−CH2), 3.45−3.47 (m, 4H, N−CH2), 6.26 (dd,
1H, 3J = 7.7 Hz, 4J = 2.8 Hz, HPyridinyl), 6.63 (dd, 1H, 3J = 8.3 Hz, 4J =
2.5 Hz, HPyridinyl), 7.03−7.09 (m, 4H, HAryl), 7.17−7.20 (m, 1H, HAryl),
7.40−7.47 (m, 4H, HAryl), 7.60−7.69 (m, 1H, HPyridinyl), 11.66 (br s,
2H, NH) ppm. 13C NMR (75.5 MHz, DMSO-d6): δ 45.29, 47.29,
2
4
74.17, 95.34 (d, J = 37 Hz), 103.48 (d, J = 3.2 Hz), 118.20, 119.40,
124.17, 129.44, 129.67, 130.23, 142.62 (d, 3J = 8.0 Hz), 149.41,
3
1
155.74, 157.60, 157.88 (d, J = 15.9 Hz), 162.02 (d, J = 233 Hz),
169.98 ppm. 19F NMR (282 MHz, DMSO-d6): δ −68.70 ppm. HRMS-
ESI: calcd for C25H22FN5O4 ([M + H]+), 476.1729; found 476.1724.
Anal. Calcd for C25H22FN5O4: C 63.15, H 4.66, N 14.73. Found: C
62.96, H 4.80, N 14.46.
4-Fluoro-N-(2-{2-[2-(2-{4-[2,4,6-trioxo-5-(4-phenoxyphenyl)-
hexahydropyrimidin-5-yl]piperazin-1-yl}ethoxy)ethoxy]-
ethoxy}ethyl)benzamide (14). TEA (0.1 mL, 0.72 mmol) was
added to a solution of 12 (150 mg, 0.27 mmol) in CH2Cl2 (4 mL),
followed by N-succinimidyl-4-fluorobenzoate (70 mg, 0.30 mmol).
5-[4-(2-{2-[2-(2-{1-[2-(2-{2-[2-(2-Fluoropyridin-3-yloxy)-
ethoxy]ethoxy}ethoxy)ethyl]-1H-1,2,3-triazol-4-ylmethoxy}-
ethoxy)ethoxy]ethoxy}ethyl)piperazin-1-yl]-5-(4-
phenoxyphenyl)pyrimidine-2,4,6-trione (32). For the preparation
229
dx.doi.org/10.1021/jm201142w | J. Med. Chem. 2012, 55, 223−232